Then on April 21, 2015, Perrigo rejected the offer and told investors that the Mylan offer undervalued Perrigo stock. Then on November 13, 2015, a majority of Perrigo's shareholders rejected to tender their shares, thus defeating Mylan's tender offer. Since the rejection of this offer, Perrigo's CEO resigned, lowered its 2016 earnings guidance and also incurred a $185 million impairment charge related to its acquisition of Omega Pharma. Plaintiff seeks to recover damages on behalf of all purchasers of Perrigo securities during the Class Period (the "Class"). If you wish to serve as lead plaintiff, you must move the Court no later than July 18, 2016. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. Note: Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.